Moreover, an enhancement in the CD8+ cells and CD8+/Treg ratio in tumor-infiltrated lymphocytes was observed in mice receiving the anti-CTLA-4 encapsulated in nanocarriers [60]. Here, CD8A is linked to neoplasm.